Novel therapy reduces damage caused by heart attack

HOLTE, Denmark - May 13, 2019 - PRLog -- ResoTher Pharma ApS is a privately held biotechnology company founded by a Danish-Anglo team of professors from the University of Copenhagen and Queen Mary University, London. The company is focused on developing a new class of therapeutics for resolution of inflammatory responses, such as that underlying some cardiovascular conditions.

Cardiovascular disease is the largest cause of death globally and its prevalence is increasing linked, in part, to rising levels of diabetes, obesity and high blood pressure.

ResoTher is preparing the clinical validation of a novel peptide drug candidate to be used as a cardioprotective treatment for patients who have suffered a Myocardial Infarction (MI), commonly known as a heart attack. In the days post-MI the inflammatory response causes further damage to the heart. Survivors of MI often suffer chronic heart failure, leading to frequent hospitalisation and long-term debility, including early death.

Animal studies with the drug have already shown very promising cardioprotective effects: a decrease of myocardial damage (52%) and an overall improvement of the survival rate after an MI (400%).

Through the specific activation of the patient's own immune resolution response, the drug is expected to provide an unprecedented level of cardioprotection, improving patient outcomes in combination with current standard of care.

'The inflammatory cascade caused by a heart attack is a destructive thing. The immune cells cause a lot of damage to the tissue, often resulting in a weak heart with excessive scar tissue. This may be avoided by triggering the resolution process because it directly dampens the source of the inflammation and starts the 'clean-up' process that heals the tissue. Currently all the biological treatments inhibit the inflammation phase itself but don't do anything to kick-start the regeneration phase. We greatly believe in the potential of this as a brand- new, innovative treatment concept, relying on many years of world-class science from the group at Barts and the London School of Medicine" says Dr. Lone Veng, CEO of ResoTher.

The first clinical trial of the drug is targeted to start in 2020. Successful development could see the treatment being used in wide-spread practice within seven years.

For further information please visit https://resotherpharma.com